Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-101 plus SBRT for limited metastatic pancreatic cancer
NL-OMON54853Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IMM-101 in pancreatic adenocarcinoma (PDAC), sponsored by Erasmus MC. Started Feb 2021; status: completed.
02
Drugs
IMM-101
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON54853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54853.